CatSci’s purpose is to get new medicines into the hands of patients in need. With a core focus on chemical development of new drug substances in pre-clinical and early clinical phases, the company has laboratories that focus on small molecules and oligonucleotides across two UK sites, and has done business in 13 countries and works with four of the top five global pharmaceutical companies. The company currently employs over 120 people, of which over 70% hold a PhD degree. CatSci is committed to breaking down the silos in drug development to support the delivery of best-in-class therapeutics.
Location: United Kingdom, Wales, Cardiff
Investors 1
| Date | Name | Website |
| - | Keensight ... | keensightc... |
Mentions in press and media 1
| Date | Title | Description |
| 25.06.2024 | CatSci announces strategic acquisition of Reach Separations to offer end-to-end separation science support | - |